[Finished Printing? - Click Here to Return to Normal View]


NIDA Home > Funding > Funding Strategy for FY 2008    

NIDA FY 2009 Funding Strategy



Based on the enacted Omnibus appropriation, the National Institute on Drug Abuse (NIDA) has established the following funding policy.

New and Competing (Type 1 & 2)

New and competing grants will be funded at a 3% increase over FY 2008.

Non-competing Continuations (Type 5)

New Investigators

  • NIDA is committed to supporting first-time R01 investigators and Early Stage Investigators (by NIH definition). This means new investigator status will be considered in funding decisions and is one factor in funding grants beyond the normal payline. For the policy on New and Early Stage Investigators go to http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-013.html.

Ruth L. Kirschstein National Research Service Awards (NRSA)

NIH has established new increased stipend levels for fiscal year 2009 NRSA awards. For more information visit http://grants.nih.gov/grants/guide/notice-files/NOT-OD-09-075.html


drugabuse.gov graphic



NIDA Home | Site Map | Search | FAQs | Accessibility | Privacy | FOIA (NIH) | Employment |



National Institutes of Health logo_Department of Health and Human Services Logo The National Institute on Drug Abuse (NIDA) is part of the National Institutes of Health (NIH) , a component of the U.S. Department of Health and Human Services. Questions? See our Contact Information. Last updated on Wednesday, April 1, 2009. The U.S. government's official web portal